Lv65
2534 积分 2024-02-11 加入
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
1天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1天前
已完结
Discovery and structure–activity relationships of small molecules that block the human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein–protein interaction
11天前
已完结
Virtual Screening Combined with Phase Transition-FRET for Discovery of Small-Molecule FcRn Antagonists
11天前
已完结
The therapeutic age of the neonatal Fc receptor
16天前
已完结
In silico investigation of molecular mechanisms underlying the function of NLuc and its variants
21天前
已完结
Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment
30天前
已完结
Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C
1个月前
已完结
Real-Time Luminescence Assay for Cytoplasmic Cargo Delivery of Extracellular Vesicles
1个月前
已完结
Discovery of Novel Inhibitors for WD Repeat‐Containing Protein 5 (WDR5)‐MYC Protein–Protein Interaction
2个月前
已完结
皖公网安备34019202002308
